

CELLINK IS LAUNCHING NEW BIOINKS

Today, CELLINK is announcing the first phase of a multiphase bioink expansion. This first phase includes the announcement of two new bioink-series product lines and the expansion of an existing line. With this launch, the company will strengthen its product portfolio and offer a wider range of tools for researchers around the world to use in their research. Additional phases of the initiative will be announced soon but will continue to expand the offerings to best serve the needs of CELLINK's collaborators.

The three categories are;

Collagen-series:

The company is launching a new bioink-series that is based around collagen as its primary component. Collagen is the main structural component found in many tissues and is the most abundant protein in mammals. The **Collagen-series** will provide both bioinks and 3D cell culture materials derived from this critical protein. These products will have applications in both the bioprinting and 3D cell culture fields. Potential applications include research in tissue development, cell migration, and drug screening.

Additive-Series:

Cells and tissues in the body can be extremely multifaceted in their roles, structures, and compositions. To complement CELLINK's standardized and ready to print bioinks, the company are announcing the **Additive-series** to allow collaborators to better tailor and customize the bioinks toward their specific applications. These additives can either be blended into existing bioinks, combined with kits, or to be mixed with the researchers own bioink. With this, CELLINK will provide a comprehensive flexibility in composing bioinks anywhere on the market. These additives combinations can impart unique and tissue specific mechanical characteristics and properties based on what is used.

Expansion of the GelMA and Alginate Product Line

Finally, CELLINK is announcing an expansion of existing **GelMA-series** and **Alginate-series**. Both the available GelMA and Alginate lines will be expanded to include more variety in molecular weight, methacrylation degree, and formulation. New offerings in formulations include sterilized and lyophilized powders, new kits for reconstitutions, and high concentration ready to dilute and print versions to build on our best selling GelMA and Alginate based standardized bioinks.

For further information, please contact:

Erik Gatenholm, CEO
Phone: +46 73 267 00 00
E-mail: eg@cellink.com

Gusten Danielsson, CFO
Phone: +46 70 991 86 04
E-mail: gd@cellink.com

About CELLINK

CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. CELLINK is listed at Nasdaq First North with the ticker CLNK. Erik Penser Bank AB, tel: +46 8 463 80 00, is the Company's Certified Adviser.